certolizumab: Certolizumab Pegol (CZP) for Rheumatoid Arthritis

In gemtc: Network Meta-Analysis Using Bayesian Methods

Certolizumab Pegol (CZP) for Rheumatoid Arthritis

Description

A dataset of 12 trials investigating 6 treatments and placebo for rheumatoid arthritis. The main outcome is the number of patients who improved by at least 50% on the American College of Rheumatology scale (ACR50) at 6 Months. A covariate is present for the mean disease duration at baseline (years).

Format

A network meta-regression dataset containing 24 rows of arm-based data (responders and sample size).

Source

S. Dias, A.J. Sutton, N.J. Welton, and A.E. Ades (2013b), Heterogeneity - Subgroups, Meta-Regression, Bias, and Bias-Adjustment, Medical Decision Making 33(5):618-640.
[\Sexpr[results=rd]{tools:::Rd_expr_doi("10.1177/0272989X13485157")}]

Examples

# Run RE regression model with informative heterogeneity prior

regressor <- list(coefficient='shared',
                  variable='diseaseDuration',
                  control='Placebo')

# sd ~ half-Normal(mean=0, sd=0.32)
hy.prior <- mtc.hy.prior(type="std.dev", distr="dhnorm", 0, 9.77)

model <- mtc.model(certolizumab,
                   type="regression",
                   regressor=regressor,
                   hy.prior=hy.prior)

## Not run: 
result <- mtc.run(model)
## End(Not run)

gemtc documentation built on July 9, 2023, 5:33 p.m.